Who are dexmedetomidine 80 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low-dose Dexmedetomidine, Preemptive Dexmedetomidine injection, tetracaine HCl and oxymetazoline HCL, Dexmedetomidine 01, Precedex (Dexmedetomidine), Butorphanol and dexmedetomindine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-80-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

dexmedetomidine 80 µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dexmedetomidine 80 µg (dexmedetomidine 80 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia and Sedation.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia and Sedation Small molecule Live · refreshed every 30 min

Target snapshot

dexmedetomidine 80 µg (dexmedetomidine 80 µg) — Fayoum University Hospital. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
dexmedetomidine 80 µg TARGET	dexmedetomidine 80 µg	Fayoum University Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Low-dose Dexmedetomidine	Low-dose Dexmedetomidine	Tang-Du Hospital	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Preemptive Dexmedetomidine injection	Preemptive Dexmedetomidine injection	China International Neuroscience Institution	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
tetracaine HCl and oxymetazoline HCL	tetracaine HCl and oxymetazoline HCL	Louisiana State University Health Sciences Center in New Orleans	marketed	Local anesthetic with vasoconstrictor combination	Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)
Dexmedetomidine 01	Dexmedetomidine 01	Guangzhou General Hospital of Guangzhou Military Command	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Precedex (Dexmedetomidine)	Precedex (Dexmedetomidine)	Icahn School of Medicine at Mount Sinai	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Butorphanol and dexmedetomindine	Butorphanol and dexmedetomindine	The Affiliated Hospital of Qingdao University	marketed	Opioid agonist-antagonist combined with alpha-2 adrenergic agonist	Opioid receptors (kappa, sigma, mu) and alpha-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

Allergan · 3 drugs in this class
Eye & ENT Hospital of Fudan University · 2 drugs in this class
National Cancer Institute, Egypt · 2 drugs in this class
The University of Hong Kong · 2 drugs in this class
Sindh Institute of Urology and Transplantation · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dexmedetomidine 80 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-80-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab